Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00777257 · ClinicalTrials.gov registry record · Phase 4
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,345
- Enrollment target
NCT00777257: Completed Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT00777257 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,345 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (160% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00777257, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,345 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and Tdap vaccine in adolescents aged 11 to 17 years. Primary Objective: To determine whether concomitant administration of two vaccines, Tdap and Menactra®, induces antibody responses that are similar to those observed when each vaccine is given separately. Secondary Objective: To compare the rates of injection site reactions at the Tdap injection site after Tdap and Menactra® vaccines are administered concomitantly to the corresponding rates of reactions when Tdap vaccine is administered alone.
Interventions
- BIOLOGICAL T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.
- BIOLOGICAL Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.
- BIOLOGICAL Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,345 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
What the finished NCT00777257 record still lists
NCT00777257 is an interventional study that assigns participants to a tested intervention. Its 1,345 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (160% higher).
The record links to 0 conditions, and to 3 interventions - of which T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj. is the first listed.
NCT00777257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00777257 about?
NCT00777257 is a clinical study titled "Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine". The purpose of this study was to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and Tdap vaccine in adolescents aged 11 to 17 years. Primary Objective: To determine whether concomitant administration of two vaccines, Tdap and Menactra®, induces antibo...
What is the current status of trial NCT00777257?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,345 participants. The study started on 2005-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00777257?
The interventions under investigation include: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj. (BIOLOGICAL), Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj. (BIOLOGICAL), Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap (BIOLOGICAL).
Who is sponsoring clinical trial NCT00777257?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00777257's enrollment target sits among peer trials
1,345 56th of 2000 higher than 1,945 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia